Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou-Alfa, Teresa Macarulla, Milind M. Javle, Robin K. Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian G. Murphy, Do Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin WuChristina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Fingerprint

Dive into the research topics of 'Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences